Literature DB >> 19687238

Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.

R J Suchland1, K M Sandoz, B M Jeffrey, W E Stamm, D D Rockey.   

Abstract

There are no examples of stable tetracycline resistance in clinical strains of Chlamydia trachomatis. However, the swine pathogen Chlamydia suis is commonly tetracycline resistant, both in America and in Europe. In tested U.S. strains, this resistance is mediated by a genomic island carrying a tet(C) allele. In the present study, the ability of C. suis to mobilize tet(C) into other chlamydial species was examined. Differently antibiotic resistant strains of C. suis, C. trachomatis, and Chlamydia muridarum were used in coculture experiments to select for multiply antibiotic resistant progeny. Coinfection of mammalian cells with a naturally occurring tetracycline-resistant strain of C. suis and a C. muridarum or C. trachomatis strain containing selected mutations encoding rifampin (rifampicin) or ofloxacin resistance readily produced doubly resistant recombinant clones that demonstrated the acquisition of tetracycline resistance. The resistance phenotype in the progeny from a C. trachomatis L2/ofl(R)-C. suis R19/tet(R) cross resulted from integration of a 40-kb fragment into a single ribosomal operon of a recipient, leading to a merodiploid structure containing three rRNA operons. In contrast, a cross between C. suis R19/tet(R) and C. muridarum MoPn/ofl(R) led to a classical double-crossover event transferring 99 kb of DNA from C. suis R19/tet(R) into C. muridarum MoPn/ofl(R). Tetracycline resistance was also transferred to recent clinical strains of C. trachomatis. Successful crosses were not obtained when a rifampin-resistant Chlamydophila caviae strain was used as a recipient for crosses with C. suis or C. trachomatis. These findings provide a platform for further exploration of the biology of horizontal gene transfer in Chlamydia while bringing to light potential public health concerns generated by the possibility of acquisition of tetracycline resistance by human chlamydial pathogens.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19687238      PMCID: PMC2772348          DOI: 10.1128/AAC.00477-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Molecular evolution of the Chlamydiaceae.

Authors:  R M Bush; K D Everett
Journal:  Int J Syst Evol Microbiol       Date:  2001-01       Impact factor: 2.747

Review 2.  Proteins in the chlamydial inclusion membrane.

Authors:  Daniel D Rockey; Marci A Scidmore; John P Bannantine; Wendy J Brown
Journal:  Microbes Infect       Date:  2002-03       Impact factor: 2.700

Review 3.  Animal chlamydioses and zoonotic implications.

Authors:  D Longbottom; L J Coulter
Journal:  J Comp Pathol       Date:  2003-05       Impact factor: 1.311

4.  Longitudinal assessment of infecting serovars of Chlamydia trachomatis in Seattle public health clinics: 1988-1996.

Authors:  Robert J Suchland; Linda O Eckert; Stephen E Hawes; Walter E Stamm
Journal:  Sex Transm Dis       Date:  2003-04       Impact factor: 2.830

5.  Recombination in the ompA gene but not the omcB gene of Chlamydia contributes to serovar-specific differences in tissue tropism, immune surveillance, and persistence of the organism.

Authors:  K L Millman; S Tavaré; D Dean
Journal:  J Bacteriol       Date:  2001-10       Impact factor: 3.490

6.  Isolates of Chlamydia trachomatis that occupy nonfusogenic inclusions lack IncA, a protein localized to the inclusion membrane.

Authors:  R J Suchland; D D Rockey; J P Bannantine; W E Stamm
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

7.  Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure.

Authors:  J Somani; V B Bhullar; K A Workowski; C E Farshy; C M Black
Journal:  J Infect Dis       Date:  2000-04-13       Impact factor: 5.226

8.  Identification of concomitant infection with Chlamydia trachomatis IncA-negative mutant and wild-type strains by genomic, transcriptional, and biological characterizations.

Authors:  Robert J Suchland; Brendan M Jeffrey; Minsheng Xia; Ajay Bhatia; Hencelyn G Chu; Daniel D Rockey; Walter E Stamm
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

9.  Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp.

Authors:  R J Suchland; W M Geisler; Walter E Stamm
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

10.  A global non-conjugative Tet C plasmid, pRAS3, from Aeromonas salmonicida.

Authors:  Trine M L'Abée-Lund; Henning Sørum
Journal:  Plasmid       Date:  2002-05       Impact factor: 3.466

View more
  57 in total

Review 1.  Antibiotic resistance in Chlamydiae.

Authors:  Kelsi M Sandoz; Daniel D Rockey
Journal:  Future Microbiol       Date:  2010-09       Impact factor: 3.165

2.  Resistance to a novel antichlamydial compound is mediated through mutations in Chlamydia trachomatis secY.

Authors:  Kelsi M Sandoz; Steven G Eriksen; Brendan M Jeffrey; Robert J Suchland; Timothy E Putman; Dennis E Hruby; Robert Jordan; Daniel D Rockey
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

Review 3.  A Coming of Age Story: Chlamydia in the Post-Genetic Era.

Authors:  Anna J Hooppaw; Derek J Fisher
Journal:  Infect Immun       Date:  2015-12-14       Impact factor: 3.441

4.  Beyond Tryptophan Synthase: Identification of Genes That Contribute to Chlamydia trachomatis Survival during Gamma Interferon-Induced Persistence and Reactivation.

Authors:  Matthew K Muramatsu; Julie A Brothwell; Barry D Stein; Timothy E Putman; Daniel D Rockey; David E Nelson
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

5.  Interrogating Genes That Mediate Chlamydia trachomatis Survival in Cell Culture Using Conditional Mutants and Recombination.

Authors:  Julie A Brothwell; Matthew K Muramatsu; Evelyn Toh; Daniel D Rockey; Timothy E Putman; Michael L Barta; P Scott Hefty; Robert J Suchland; David E Nelson
Journal:  J Bacteriol       Date:  2016-07-13       Impact factor: 3.490

6.  Generation of targeted Chlamydia trachomatis null mutants.

Authors:  Laszlo Kari; Morgan M Goheen; Linnell B Randall; Lacey D Taylor; John H Carlson; William M Whitmire; Dezso Virok; Krithika Rajaram; Valeria Endresz; Grant McClarty; David E Nelson; Harlan D Caldwell
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

Review 7.  Emancipating Chlamydia: Advances in the Genetic Manipulation of a Recalcitrant Intracellular Pathogen.

Authors:  Robert J Bastidas; Raphael H Valdivia
Journal:  Microbiol Mol Biol Rev       Date:  2016-03-30       Impact factor: 11.056

8.  Chlamydia Lipooligosaccharide Has Varied Direct and Indirect Roles in Evading both Innate and Adaptive Host Immune Responses.

Authors:  Xisheng Wang; Daniel D Rockey; Brian P Dolan
Journal:  Infect Immun       Date:  2020-07-21       Impact factor: 3.441

9.  Trypanosoma cruzi Differentiates and Multiplies within Chimeric Parasitophorous Vacuoles in Macrophages Coinfected with Leishmania amazonensis.

Authors:  Carina Carraro Pessoa; Éden Ramalho Ferreira; Ethel Bayer-Santos; Michel Rabinovitch; Renato Arruda Mortara; Fernando Real
Journal:  Infect Immun       Date:  2016-04-22       Impact factor: 3.441

10.  Forward genetic approaches in Chlamydia trachomatis.

Authors:  Bidong D Nguyen; Raphael H Valdivia
Journal:  J Vis Exp       Date:  2013-10-23       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.